Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mucosal immunity preparation capable of resisting infection and tumors

A technology of mucosal immunity and anti-infection, applied in the field of immunology, can solve the problem of weak induction

Active Publication Date: 2019-01-04
林海祥 +3
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Polyinosinic acid-polycytidylic acid is a synthetic analogue of double-stranded RNA that mimics viruses. It is a ligand for TLR3, RIG-I and MDA5 receptors, and can induce high titers in animals or in cell culture. The IFN-a of IFN-a in humans and monkeys is relatively weak, because there are nucleases in primate blood to degrade polyinosinic acid-polycytidylic acid. Therefore, there are many ways in the prior art to improve polyosinic acid inosinic acid-polycytidylic acid deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucosal immunity preparation capable of resisting infection and tumors
  • Mucosal immunity preparation capable of resisting infection and tumors
  • Mucosal immunity preparation capable of resisting infection and tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Embodiment 1 mucosal immune preparation and preparation method thereof

[0078] (1) Using polyinosinic acid and polycytidylic acid as raw materials, use PBS buffer to prepare polyinosinic acid solution and polycytidylic acid solution; stir at 30-60 ° C to prepare 0.5-10 mg / mL double-stranded poly Inosinic acid-polycytidylic acid solution (PIC solution);

[0079] (2) Oligochitosan solution (COS solution) with a concentration of 1.6 to 12.8 mg / mL was formulated with PBS buffer solution;

[0080] (3) Add the COS solution dropwise to the double-stranded polyinosinic acid-polycytidylic acid solution obtained in step (1), add dropwise while stirring, then add the PEI solution dropwise under stirring, and then add dropwise under stirring CaCl 2 solution to obtain a mucosal immune substance sample solution;

[0081] (4) The mucosal immune substance sample solution prepared above is sterilized and filtered and distributed into suitable spray bottles or aerosol bottles to obta...

Embodiment 2

[0082] Example 2 Mucosal immune preparation and preparation method thereof

[0083] (1) Using polyinosinic acid and polycytidylic acid as raw materials, use PBS buffer to prepare polyinosinic acid solution and polycytidylic acid solution; stir at 30-60 ° C to prepare 0.5-10 mg / mL double-stranded poly Inosinic acid-polycytidylic acid solution (PIC solution);

[0084] (2) Oligochitosan solution (COS solution) with a concentration of 1.6 to 12.8 mg / mL was formulated with PBS buffer solution;

[0085] Or use PBS buffer to prepare PEG-g-COS into a PEG-g-COS solution with a concentration of 1.6-51.2mg / mL;

[0086] (3) Add PEG-g-COS solution or chitosan oligosaccharide solution dropwise to the double-stranded polyinosinic acid-polycytidylic acid solution obtained in step (1), add dropwise while stirring, and then add dropwise under stirring CaCl 2 solution to obtain PIC-PEG-g-COS-CaCl 2 or PIC-COS-CaCl 2 Complex;

[0087] (4) Mix PIC-PEG-g-COS-CaCl on a constant temperature mag...

experiment example 1

[0089] Experimental Example 1 Nasal Drops Mucosal Immunization Preparation Alone Anti-Influenza Mice Protection Test

[0090] Influenza virus: Subtype A murine lung-adapted strain FM1, purchased from the Institute of Viral Disease Control, Chinese Academy of Preventive Medicine.

[0091] Ribavirin: positive control drug, purchased from Shenyang Yanfeng Pharmaceutical Factory.

[0092] White mice: Kunming species, 8-10g for FM1 virus subculture, 14-20g for the following formal experiments.

[0093] Influenza virus FM1 strain mouse lung suspension with 5LD 50 / only can cause lethal pneumonia by intranasally dripping to mice, infect earlier during the test and then administer the drug, and carry out the grouping test according to Table 1.

[0094] Table 1 Mucosal immune preparation of the present invention nasal drop method anti-influenza mouse protection test

[0095]

[0096] The experimental results show that in the mouse protection test, the nasal drops of the present ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of immunology, and particularly discloses a mucosal immunity preparation capable of resisting infection and tumors. The effective component of the preparation is a mucosal immunity substance which is formed by combining polyinosinic acid-polycytidylic acid, a non-antibiotic amino compound, metal positive ions, and PEG and / or PEI and / or PLGA and / or positive ion polymers through hydrogen bonds and other chemical bonds. The preparation is a spray or an aerosol in dosage form, but preferentially, the preparation does not contain ingredients utilized by common sprays or ingredients utilized by aerosols, and propellants. The mucosal immunity preparation can achieve the slow-release function partially or wholly, the half-life period of the mucosal immunity preparation is prolonged, the availability and effectiveness of drugs are improved, and the compliance of a patient is improved. The mucosal immunity preparation can promote mucosal immunity of the human body by means of the mucosal immunity, and then promote activation and proliferation, including whole-body nonspecific immunity, humoral immunity and cellular immunity, of all immune cells instead of only acting on the local part of a disease wound, and thus the preventing and treating effects of resisting infection and tumors are achieved.

Description

technical field [0001] The invention relates to the field of immunology, in particular to an anti-infection and anti-tumor mucosal immune preparation. Background technique [0002] Anti-tumor and anti-viral treatment is a major problem at present. Anti-tumor surgery, radiotherapy, chemotherapy and immunotherapy such as PD1 / PD-L1 and CTLA4 are aimed at the local tumor or local environment, and have poor effect on metastatic cancer; the current antiviral vaccines are all preventive, Not for therapeutic use. [0003] The mucosal immune system is widely distributed in the mucosal tissues of the respiratory system, digestive system, genitourinary system, and some exocrine glands, and is the main site for local or systemic immune responses. The mucosal immune system mainly secretes IgA antibodies, and some IgD, IgE, etc., of course there are some other substances, but these antibodies are the main ones. [0004] Usually, the induction of immunization by injection is mainly base...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/12A61K31/713A61K31/722A61K33/06A61P35/00A61P31/12A61P31/04A61P33/00A61K31/765A61K31/785
CPCA61K9/0014A61K9/0034A61K9/0048A61K9/0053A61K9/0073A61K31/713A61K31/722A61K31/765A61K31/785A61K33/06A61K9/12A61K2300/00A61K39/39A61K2039/541A61K9/0043A61K9/008A61K47/34A61K2039/543A61K2039/6087A61K2039/6093A61K47/36A61P31/04A61P31/12A61P33/00A61P35/00A61K39/145A61K2039/60A61K2039/544
Inventor 林海祥刘芳查力孙晓林
Owner 林海祥
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com